Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles.

Lerche S, Wurster I, Roeben B, Zimmermann M, Riebenbauer B, Deuschle C, Hauser AK, Schulte C, Berg D, Maetzler W, Waniek K, Lachmann I, Liepelt-Scarfone I, Gasser T, Brockmann K.

Mov Disord. 2019 Oct 30. doi: 10.1002/mds.27884. [Epub ahead of print]

PMID:
31670439
2.

Do longitudinal cerebrospinal fluid profiles correspond to postmortem brain pathology in LRRK2 Parkinson's disease?

Wurster I, Lerche S, Hauser AK, Schulte C, Lachmann I, Beschorner R, Neumann M, Brockmann K.

Eur J Neurol. 2020 Jan;27(1):e5-e6. doi: 10.1111/ene.14060. Epub 2019 Sep 10. No abstract available.

PMID:
31420996
3.

Orthostatic hypotension as a risk factor for longitudinal deterioration of cognitive function in the elderly.

Zimmermann M, Wurster I, Lerche S, Roeben B, Machetanz G, Sünkel U, von Thaler AK, Eschweiler G, Fallgatter AJ, Maetzler W, Berg D, Brockmann K.

Eur J Neurol. 2020 Jan;27(1):160-167. doi: 10.1111/ene.14050. Epub 2019 Aug 26.

PMID:
31342593
4.

The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.

Agesen RM, Alibegovic AC, Andersen HU, Beck-Nielsen H, Gustenhoff P, Hansen TK, Hedetoft C, Jensen T, Juhl CB, Lerche SS, Nørgaard K, Parving HH, Tarnow L, Thorsteinsson B, Pedersen-Bjergaard U.

BMC Endocr Disord. 2019 Jul 23;19(1):78. doi: 10.1186/s12902-019-0408-x.

5.

Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile.

Lerche S, Machetanz G, Wurster I, Roeben B, Zimmermann M, Pilotto A, Preische O, Stransky E, Deuschle C, Hauser AK, Schulte C, Lachmann I, Waniek K, Gasser T, Berg D, Maetzler W, Brockmann K.

Mov Disord. 2019 Jul;34(7):1069-1073. doi: 10.1002/mds.27731. Epub 2019 Jun 12.

PMID:
31189032
6.

REM sleep behaviour disorder (RBD): risk for Parkinsonism and executive dysfunction in elderly.

Lerche S, Brockmann K.

Oncotarget. 2018 Dec 4;9(95):36732-36733. doi: 10.18632/oncotarget.26417. eCollection 2018 Dec 4. No abstract available.

7.

Parkinson's disease: evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study.

Lerche S, Wurster I, Röben B, Machetanz G, Zimmermann M, Bernhard F, Stransky E, Deuschle C, Schulte C, Hansson O, Zetterberg H, Gasser T, Berg D, Maetzler W, Brockmann K.

J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):165-170. doi: 10.1136/jnnp-2018-318956. Epub 2018 Sep 25.

PMID:
30254084
8.

Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease.

Lerche S, Liepelt-Scarfone I, Wurster I, Schulte C, Schäffer E, Röben B, Machetanz G, Zimmermann M, Akbas S, Hauser AK, Gasser T, Maetzler W, Berg D, Brockmann K.

Mov Disord. 2018 Aug;33(8):1349-1353. doi: 10.1002/mds.27427. Epub 2018 Aug 22.

PMID:
30132985
9.

Deterioration of executive dysfunction in elderly with REM sleep behavior disorder (RBD).

Lerche S, Machetanz G, Roeben B, Wurster I, Zimmermann M, von Thaler AK, Liepelt-Scarfone I, Eschweiler GW, Fallgatter A, Metzger F, Maetzler W, Berg D, Brockmann K.

Neurobiol Aging. 2018 Oct;70:242-246. doi: 10.1016/j.neurobiolaging.2018.06.029. Epub 2018 Jun 30.

PMID:
30048891
10.

Effect of physical activity on cognitive flexibility, depression and RBD in healthy elderly.

Lerche S, Gutfreund A, Brockmann K, Hobert MA, Wurster I, Sünkel U, Eschweiler GW, Metzger FG, Maetzler W, Berg D.

Clin Neurol Neurosurg. 2018 Feb;165:88-93. doi: 10.1016/j.clineuro.2018.01.008. Epub 2018 Jan 9.

PMID:
29331872
11.

SNPs in Aβ clearance proteins: Lower CSF Aβ1-42 levels and earlier onset of dementia in PD.

Brockmann K, Lerche S, Dilger SS, Stirnkorb JG, Apel A, Hauser AK, Liepelt-Scarfone I, Berg D, Gasser T, Schulte C, Maetzler W.

Neurology. 2017 Dec 5;89(23):2335-2340. doi: 10.1212/WNL.0000000000004705. Epub 2017 Nov 8.

PMID:
29117956
12.

Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles.

Lerche S, Schulte C, Srulijes K, Pilotto A, Rattay TW, Hauser AK, Stransky E, Deuschle C, Csoti I, Lachmann I, Zetterberg H, Liepelt-Scarfone I, Gasser T, Maetzler W, Berg D, Brockmann K.

Mov Disord. 2017 Dec;32(12):1780-1783. doi: 10.1002/mds.27199. Epub 2017 Nov 2.

PMID:
29094781
13.

Global, Yet Incomplete Overview of Cohort Studies in Parkinson's disease.

Heinzel S, Lerche S, Maetzler W, Berg D.

J Parkinsons Dis. 2017;7(3):423-432. doi: 10.3233/JPD-171100. Review.

PMID:
28582871
14.

Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts.

Pilotto A, Heinzel S, Suenkel U, Lerche S, Brockmann K, Roeben B, Schaeffer E, Wurster I, Yilmaz R, Liepelt-Scarfone I, von Thaler AK, Metzger FG, Eschweiler GW, Postuma RB, Maetzler W, Berg D.

Mov Disord. 2017 Jul;32(7):1025-1034. doi: 10.1002/mds.27035. Epub 2017 May 16.

PMID:
28509336
15.

Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs.

Lerche S, Brockmann K, Pilotto A, Wurster I, Sünkel U, Hobert MA, von Thaler AK, Schulte C, Stoops E, Vanderstichele H, Herbst V, Brix B, Eschweiler GW, Metzger FG, Maetzler W, Berg D.

Alzheimers Res Ther. 2016 Oct 10;8(1):42.

16.

Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned.

Heinzel S, Roeben B, Ben-Shlomo Y, Lerche S, Alves G, Barone P, Behnke S, Berendse HW, Bloem BR, Burn D, Dodel R, Grosset DG, Hu M, Kasten M, Krüger R, Moccia M, Mollenhauer B, Oertel W, Suenkel U, Walter U, Wirdefeldt K, Liepelt-Scarfone I, Maetzler W, Berg D.

Front Aging Neurosci. 2016 Jun 22;8:147. doi: 10.3389/fnagi.2016.00147. eCollection 2016. Review.

17.

Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies.

Lerche S, Heinzel S, Alves GW, Barone P, Behnke S, Ben-Shlomo Y, Berendse H, Bloem BR, Burn D, Dodel R, Grosset DG, Hipp G, Hu MT, Kasten M, Krüger R, Liepelt-Scarfone I, Maetzler W, Moccia M, Mollenhauer B, Oertel W, Roeben B, Walter U, Wirdefeldt K, Berg D.

Front Aging Neurosci. 2016 May 27;8:121. doi: 10.3389/fnagi.2016.00121. eCollection 2016. No abstract available.

18.

GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia.

Maetzler W, Deleersnijder W, Hanssens V, Bernard A, Brockmann K, Marquetand J, Wurster I, Rattay TW, Roncoroni L, Schaeffer E, Lerche S, Apel A, Deuschle C, Berg D.

PLoS One. 2016 Mar 3;11(3):e0149349. doi: 10.1371/journal.pone.0149349. eCollection 2016.

19.

Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease--Report of the JPND Working Group BioLoC-PD.

Lerche S, Liepelt-Scarfone I, Alves G, Barone P, Behnke S, Ben-Shlomo Y, Berendse H, Burn D, Dodel R, Grosset D, Heinzel S, Hu M, Kasten M, Krüger R, Maetzler W, Moccia M, Mollenhauer B, Oertel W, Roeben B, Sünkel U, Walter U, Wirdefeldt K, Berg D.

Neuroepidemiology. 2015;45(4):282-97. doi: 10.1159/000439221. Epub 2015 Nov 3.

20.

Reasons for mild parkinsonian signs - which constellation may indicate neurodegeneration?

Lerche S, Brockmann K, Wurster I, Gaenslen A, Roeben B, Holz D, Eschweiler GW, Maetzler W, Berg D.

Parkinsonism Relat Disord. 2015 Feb;21(2):126-30. doi: 10.1016/j.parkreldis.2014.11.018. Epub 2014 Nov 28.

PMID:
25511329
21.

Clinical characteristics related to worsening of motor function assessed by the Unified Parkinson's Disease Rating Scale in the elderly population.

Liepelt-Scarfone I, Lerche S, Behnke S, Godau J, Gaenslen A, Pausch C, Fassbender K, Brockmann K, Srulijes K, Huber H, Wurster I, Berg D.

J Neurol. 2015 Feb;262(2):451-8. doi: 10.1007/s00415-014-7584-4. Epub 2014 Dec 2.

PMID:
25451854
22.

Mild parkinsonian signs in the elderly--is there an association with PD? Crossectional findings in 992 individuals.

Lerche S, Hobert M, Brockmann K, Wurster I, Gaenslen A, Hasmann S, Eschweiler GW, Maetzler W, Berg D.

PLoS One. 2014 Mar 27;9(3):e92878. doi: 10.1371/journal.pone.0092878. eCollection 2014.

23.

Prodromal features for Parkinson's disease--baseline data from the TREND study.

Gaenslen A, Wurster I, Brockmann K, Huber H, Godau J, Faust B, Lerche S, Eschweiler GW, Maetzler W, Berg D.

Eur J Neurol. 2014 May;21(5):766-72. doi: 10.1111/ene.12382. Epub 2014 Feb 24.

PMID:
24612314
24.

Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia.

Gejl M, Lerche S, Mengel A, Møller N, Bibby BM, Smidt K, Brock B, Søndergaard H, Bøtker HE, Gjedde A, Holst JJ, Hansen SB, Rungby J.

PLoS One. 2014 Jan 6;9(1):e83758. doi: 10.1371/journal.pone.0083758. eCollection 2014.

25.

Risk factors and prodromal markers and the development of Parkinson's disease.

Lerche S, Seppi K, Behnke S, Liepelt-Scarfone I, Godau J, Mahlknecht P, Gaenslen A, Brockmann K, Srulijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Poewe W, Berg D.

J Neurol. 2014 Jan;261(1):180-7. doi: 10.1007/s00415-013-7171-0. Epub 2013 Nov 5.

PMID:
24190794
26.

The antimicrobial lysine-peptoid hybrid LP5 inhibits DNA replication and induces the SOS response in Staphylococcus aureus.

Gottschalk S, Ifrah D, Lerche S, Gottlieb CT, Cohn MT, Hiasa H, Hansen PR, Gram L, Ingmer H, Thomsen LE.

BMC Microbiol. 2013 Aug 14;13:192. doi: 10.1186/1471-2180-13-192.

27.

Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain.

Gejl M, Lerche S, Egefjord L, Brock B, Møller N, Vang K, Rodell AB, Bibby BM, Holst JJ, Rungby J, Gjedde A.

Front Neuroenergetics. 2013 Mar 27;5:2. doi: 10.3389/fnene.2013.00002. eCollection 2013.

28.

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

Berg D, Behnke S, Seppi K, Godau J, Lerche S, Mahlknecht P, Liepelt-Scarfone I, Pausch C, Schneider N, Gaenslen A, Brockmann K, Srulijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Gasser T, Poewe W.

Mov Disord. 2013 Feb;28(2):216-9. doi: 10.1002/mds.25192. Epub 2012 Oct 31.

PMID:
23115051
29.

Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia.

Gejl M, Egefjord L, Lerche S, Vang K, Bibby BM, Holst JJ, Mengel A, Møller N, Rungby J, Brock B, Gjedde A.

J Cereb Blood Flow Metab. 2012 Dec;32(12):2146-52. doi: 10.1038/jcbfm.2012.118. Epub 2012 Aug 29.

30.

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, Stockner H, Gaenslen A, Mahlknecht P, Huber H, Srulijes K, Klenk J, Fassbender K, Maetzler W, Poewe W; PRIPS study group.

Eur J Neurol. 2013 Jan;20(1):102-8. doi: 10.1111/j.1468-1331.2012.03798.x. Epub 2012 Aug 1.

PMID:
22852790
31.

Lowered serum amyloid-β1-42 autoantibodies in individuals with lifetime depression.

Maetzler W, Langkamp M, Lerche S, Godau J, Brockmann K, Gaenslen A, Huber H, Wurster I, Niebler R, Eschweiler GW, Berg D.

J Alzheimers Dis. 2012;32(1):95-100.

PMID:
22766733
32.

Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-β pathway.

Maetzler W, Stapf AK, Schulte C, Hauser AK, Lerche S, Wurster I, Schleicher E, Melms A, Berg D.

J Alzheimers Dis. 2011;27(1):119-26. doi: 10.3233/JAD-2011-110587.

PMID:
21765209
33.

Behavioural response of Phytoseiulus persimilisin inert materials for technical application.

Wendorf D, Sermann H, Katz P, Lerche S, Büttner C.

Commun Agric Appl Biol Sci. 2009;74(2):397-400.

PMID:
20222596
34.

Soil application of Beauveria bassiana to control Ceratitis capitata in semi field conditions.

Ali A, Sermann H, Lerche S, Büttner C.

Commun Agric Appl Biol Sci. 2009;74(2):357-61.

PMID:
20222591
35.

Persistence of the entomopathogenic fungus Lecanicillium muscarium Zare & Gams under ambient conditions in the field.

Lerche S, Sermann H, Büttner C.

Commun Agric Appl Biol Sci. 2009;74(2):353-6.

PMID:
20222590
36.

No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.

Lerche S, Soendergaard L, Rungby J, Moeller N, Holst JJ, Schmitz OE, Brock B.

Clin Endocrinol (Oxf). 2009 Oct;71(4):500-6. doi: 10.1111/j.1365-2265.2008.03510.x. Epub 2008 Dec 15.

PMID:
19094067
37.

Muscle RING-finger protein-1 (MuRF1) as a connector of muscle energy metabolism and protein synthesis.

Koyama S, Hata S, Witt CC, Ono Y, Lerche S, Ojima K, Chiba T, Doi N, Kitamura F, Tanaka K, Abe K, Witt SH, Rybin V, Gasch A, Franz T, Labeit S, Sorimachi H.

J Mol Biol. 2008 Mar 7;376(5):1224-36. doi: 10.1016/j.jmb.2007.11.049. Epub 2007 Nov 22.

PMID:
18222470
38.

Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2.

Witt CC, Witt SH, Lerche S, Labeit D, Back W, Labeit S.

EMBO J. 2008 Jan 23;27(2):350-60. Epub 2007 Dec 20.

39.

Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans.

Lerche S, Brock B, Rungby J, Bøtker HE, Møller N, Rodell A, Bibby BM, Holst JJ, Schmitz O, Gjedde A.

Diabetes. 2008 Feb;57(2):325-31. Epub 2007 Nov 8.

41.

Hearing impairment after prolonged dihydrostreptomycin treatment of surgical tuberculosis.

Lerche S.

Scand J Respir Dis. 1972;53(1):27-34. No abstract available.

PMID:
4115288

Supplemental Content

Loading ...
Support Center